23andMe Board resigns en masse amid CEO Anne Wojcicki's plans to take DNA testing company private

The board of directors at 23andMe, a leading DNA testing company, has resigned en masse amid disagreements over CEO Anne Wojcicki's plans to take the company private. The surprise move comes as Wojcicki seeks to take the company private in a deal valued at $4 billion.

According to sources, the board members resigned due to concerns over Wojcicki's plans to take the company private, which they believe would benefit her personally rather than the company's shareholders. The resignation of the board members is a significant blow to Wojcicki's plans, as it leaves her with no board members to support her decision.

The resignations come as 23andMe continues to grow and expand its services, including its DNA testing and genetic analysis capabilities. The company has become a leader in the biotech industry, with its DNA testing kits and services being used by millions of people around the world.

The resignation of the board members is a significant development in the biotech industry, as it highlights the challenges and controversies that can arise when a company's leadership seeks to take it private. The move is also a blow to Wojcicki, who has been a key figure in the company's success and growth.

In a statement, Wojcicki said that she was "disappointed" by the board members' decision to resign, but that she would continue to work towards taking the company private. She also stated that she believed that the company's shareholders would benefit from the deal, despite the concerns raised by the board members.

The resignation of the board members is a significant development in the biotech industry, and it remains to be seen how the situation will unfold.